// App-Quantinova.ai

e20077 : Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM).

Researchers

Presenter

  • Vanesa Gregorc

Principal Investigators

  • Alessandra Bulotta

  • Maria G Vigano

  • Giovanni Citterio

  • Giovanna Petrella

  • Elena Brioschi

  • Monika Ducceschi

  • Luca Gianni

  • Scialini Colombi

  • Gloria Rossoni

  • Giulia Salini

  • Veronica Savia

  • Antonio Lambiase

  • Claudio Bordignon

Medical Centers

  • Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy

  • MolMed, Milan, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Malignant pleural mesothelioma

  • Lung Cancer

  • Dyspnea

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • NGR-hTNF

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT01098266

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved